Hetero Labs Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Hetero Labs Limited Pharmaceutical Export Portfolio Dataset — 46 Products, $319.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hetero Labs Limited — Pharmaceutical Exporter Profile (2026) | 46 Products, $319.3M Trade | TransData Nexus

Hetero Labs Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $319.3M Total Trade · DGFT Verified

Hetero Labs Limited is an Indian pharmaceutical exporter with a total trade value of $319.3M across 46 products in 18 therapeutic categories. Based on 7,334 verified export shipments from Indian Customs (DGFT) records, Hetero Labs Limited is the #1 Indian exporter in 6 products including Ritonavir, Darunavir, Torsemide. Top exports include Tenofovir ($64.3M), Dolutegravir ($35.5M), Ritonavir ($24.7M).

Hetero Labs Limited — Export Portfolio & Destination Treemap

Hetero Labs Limited pharmaceutical export portfolio — 46 products across 18 therapeutic categories. Source: Indian Customs (DGFT).

Who is Hetero Labs Limited? — Company Overview & Market Position

Hetero Labs Limited, established on March 10, 1989, is a prominent Indian pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered at 7-2-A2, Hetero Corporate Industrial Estate, Sanathnagar, Hyderabad, Telangana 500018, India. It operates as a public unlisted company, classified as 'company limited by shares' under the Corporate Identification Number (CIN) U24110TG1989PLC009723.

Hetero Labs Limited is a subsidiary of the Hetero Group, one of India's leading generic pharmaceutical companies. The company has a significant presence in the global pharmaceutical market, exporting to over 140 countries. Its product portfolio encompasses more than 300 products across various therapeutic categories, including HIV/AIDS, oncology, cardiovascular, and neurology.

What Does Hetero Labs Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tenofovir$64.3M 2Dolutegravir

Product Portfolio — Top 30 by Export Value

Hetero Labs Limited exports 46 pharmaceutical products across 18 therapeutic categories. Market leader (#1 exporter) in 6 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tenofovir	Antiviral & HIV Medications	$64.3M	1,285	1.5%	2
2	Dolutegravir	Antiviral & HIV Medications	$35.5M	709	0.8%	2
3	Ritonavir	Antiviral & HIV Medications	$24.7M	494	7.3%	1
4	Acyclovir	Antivirals	$16.4M	327	13.0%	2
5	Valacyclovir	Antivirals	$12.6M	251	13.5%	2
6	Oseltamivir	Antivirals	$12.0M	240	9.8%	2
7	Rosuvastatin	Cardiovascular	$11.7M	239	2.5%	11
8	Gabapentin	CNS & Psychiatric	$11.6M	252	1.3%	14
9	Darunavir	Antiviral & HIV Medications	$11.3M	227	18.8%	1
10	Torsemide	Diuretics	$10.6M	246	58.0%	1
11	Esomeprazole	Gastrointestinal	$9.0M	209	2.0%	8
12	Fenofibrate	Lipid & Metabolism	$8.3M	338	11.3%	2
13	Cetirizine	Antihistamines & Allergy	$7.5M	395	4.2%	8
14	Simvastatin	Cardiovascular	$7.1M	144	5.6%	6
15	Atovaquone	Antimalarial & Antiparasitic	$6.8M	137	0.7%	3
16	Salmeterol	Respiratory	$6.4M	139	8.8%	2
17	Omeprazole	Gastrointestinal	$5.7M	133	0.9%	12
18	Sofosbuvir	Antiviral & HIV Medications	$5.3M	105	12.8%	2
19	Calcium	Vitamins & Supplements	$5.1M	131	0.6%	14
20	Lansoprazole	Gastrointestinal	$4.6M	154	1.6%	9
21	Fluticasone	Respiratory	$4.5M	112	2.2%	2
22	Metoprolol	Cardiovascular	$4.3M	156	0.5%	14
23	Indomethacin	Analgesics & Antipyretics	$3.9M	144	41.6%	1
24	Velpatasvir	Antiviral & HIV Medications	$3.7M	74	15.0%	2
25	Emtricitabine	Antiviral & HIV Medications	$3.4M	67	2.8%	6
26	Montelukast	Respiratory	$2.9M	58	1.7%	7
27	Sitagliptin	Diabetes & Endocrine	$2.8M	56	3.7%	4
28	Ezetimibe	Lipid & Metabolism	$2.7M	101	0.5%	10
29	Valsartan	Cardiovascular	$2.3M	75	1.2%	11
30	Atazanavir	Antiviral & HIV Medications	$2.1M	43	3.0%	3

Hetero Labs Limited exports 46 pharmaceutical products across 18 therapeutic categories with a total export value of $319.3M. The company is the #1 Indian exporter in 6 products: Ritonavir, Darunavir, Torsemide, Indomethacin. The top category is Antiviral & HIV Medications (47.5% of portfolio), followed by Antivirals (13.4%), reflecting a diversified portfolio where the top 5 products account for only 48.0% of total value.

Showing top 30 of 46 products. Contact us for complete data.

Hetero Labs Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Hetero Labs Limited operates multiple state-of-the-art manufacturing facilities strategically located worldwide. These facilities are approved by stringent global regulatory authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO). The company's manufacturing plants are equipped with advanced technology and adhere to Good Manufacturing Practices (GMP) to ensure the production of high-quality pharmaceutical formulations.

3Key Leadership

The leadership team at Hetero Labs Limited comprises experienced professionals committed to driving the company's growth and maintaining its reputation for quality. The key executives include:

Dr. Bandi Partha Saradhi Reddy: Chairman and Managing Director, responsible for overseeing the company's strategic direction and overall operations.

Mr. Srinivasa Reddy Male: Director, contributing to the company's strategic planning and decision-making processes.

Mr. Attunuri Venkatanarasa Reddy: Director, involved in the company's operational management and growth initiatives.

Ms. Kalavathi Bandi: Director, playing a key role in the company's governance and strategic oversight.

Mr. Vamsikrishna Bandi: Director, contributing to the company's strategic planning and operational management.

These leaders bring a wealth of experience and expertise to Hetero Labs Limited, guiding the company towards continued success in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Hetero Labs Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Hetero Labs Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from various regulatory bodies, ensuring compliance with international standards. In the United States, Hetero Labs Limited has received approval for its Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the marketing of its products in the U.S. market. Similarly, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, allowing it to supply products across EU member states. In Japan, Hetero Labs Limited has secured approvals from the Pharmaceuticals and Medical Devices Agency (PMDA), enabling the distribution of its products in the Japanese market. These regulatory approvals underscore the company's commitment to meeting the stringent requirements of regulated markets.

2Emerging Markets

Hetero Labs Limited has strategically expanded its footprint in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these markets and enhancing the availability of essential medicines. The WHO prequalification ensures that Hetero Labs Limited's products meet international quality standards, thereby increasing their acceptance among procurement agencies and healthcare providers in these regions. This strategic approach aligns with the company's mission to make affordable medicines accessible to patients worldwide.

Hetero Labs Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Hetero Labs Limited has a history of interactions with the U.S. Food and Drug Administration (FDA). In December 2016, the FDA conducted an inspection of the company's Unit V facility in Telangana, India. The inspection identified significant violations of current Good Manufacturing Practice (cGMP) regulations, leading to a warning letter issued on August 15, 2017. The warning letter highlighted issues related to the manufacturing, processing, packing, or holding of drug products, which were found to be adulterated under the Federal Food, Drug, and Cosmetic Act. The company has since taken corrective actions to address these violations and has been working towards ensuring compliance with FDA regulations.

2WHO & EU GMP

Hetero Labs Limited's commitment to quality is demonstrated by its adherence to international standards, including WHO Good Manufacturing Practice (GMP) and EU GMP certifications. The company's manufacturing facilities are WHO prequalified, ensuring that its products meet the stringent quality requirements set by the World Health Organization. Additionally, Hetero Labs Limited holds EU GMP certificates, allowing it to supply pharmaceutical formulations across European Union member states. These certifications reflect the company's dedication to maintaining high-quality manufacturing processes and product standards.

Hetero Labs Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Hetero Labs Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products across various therapeutic categories. The company's focus on high-quality manufacturing, adherence to international regulatory standards, and extensive global distribution network position it favorably in the market. While specific market share data is not available, Hetero Labs Limited's strategic initiatives and product portfolio contribute to its competitive standing in the industry.

2Key Differentiators

Hetero Labs Limited distinguishes itself through its extensive experience in the pharmaceutical sector, with over 30 years in the industry. The company's significant presence in over 140 countries and its ability to cater to 40% of the existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment underscore its global reach and expertise. Additionally, the company's adherence to international quality standards, including WHO GMP and EU GMP certifications, reinforces its commitment to delivering high-quality pharmaceutical formulations.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Hetero Labs Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Hetero Labs Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a significant export volume of $319.3 million USD across 7,334 shipments from 2022 to 2026. The

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Hetero Labs Limited

How many pharmaceutical products does Hetero Labs Limited export from India?

Hetero Labs Limited exports 46 pharmaceutical products across 18 therapeutic categories. The top exports are Tenofovir ($64.3M), Dolutegravir ($35.5M), Ritonavir ($24.7M), Acyclovir ($16.4M), Valacyclovir ($12.6M). Total export value is $319.3M.

What is Hetero Labs Limited's total pharmaceutical export value?

Hetero Labs Limited's total pharmaceutical export value is $319.3M, based on 7,334 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Hetero Labs Limited the #1 Indian exporter?

Hetero Labs Limited is the #1 Indian exporter in 6 products: Ritonavir (7.3% market share), Darunavir (18.8% market share), Torsemide (58.0% market share), Indomethacin (41.6% market share).

What therapeutic categories does Hetero Labs Limited cover?

Hetero Labs Limited exports across 18 therapeutic categories. The largest are Antiviral & HIV Medications (47.5%, 10 products), Antivirals (13.4%, 4 products), Cardiovascular (8.3%, 5 products).

Get Full Hetero Labs Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.